StaphVAX in Cardiovascular Surgery Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00211913
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : January 4, 2008
Information provided by:
Nabi Biopharmaceuticals

Brief Summary:
S. aureus is the most common pathogen encountered in infection associated with cardiovascular surgery. StaphVAX® is a bivalent S. aureus types 5 and 8 vaccine which contains the purified capsular polysaccharides (CPS) that have been implicated as a major factor in the invasiveness of S. aureus. Immunoprophylaxis by vaccinating against S. aureus prior to surgery could provide sufficient antibody concentrations during surgery and during the wound healing period so as to decrease the risk of S. aureus infection. This study aims to demonstrate the immunogenicity and safety of a single dose of StaphVAX in patients who are candidates for cardiovascular surgery.

Condition or disease Intervention/treatment Phase
Staphylococcal Infections Cardiovascular Diseases Cardiovascular Surgical Procedures Biological: S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate Biological: placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Safety and Immunogenicity of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine, in Adult Patients Undergoing Cardiovascular Surgery
Study Start Date : June 2004
Actual Primary Completion Date : October 2005
Actual Study Completion Date : January 2006

Arm Intervention/treatment
Experimental: vaccine
single dose of StaphVAX®
Biological: S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate
single IM dose totalling 200 mcg of conjugate
Other Name: StaphVAX®

Placebo Comparator: placebo
single dose
Biological: placebo
single IM dose

Primary Outcome Measures :
  1. Serotype-specific antibody concentrations [ Time Frame: 6 weeks after the vaccine dose ]

Secondary Outcome Measures :
  1. Serotype-specific antibody concentrations [ Time Frame: at other time points 7-180 days after the vaccine dose. ]
  2. adverse events [ Time Frame: 0-180 days after vaccine dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Candidate for cardiovascular surgery
  • Expected to comply with protocol
  • Negative pregnancy test where appropriate
  • Written informed consent

Exclusion Criteria:

  • Known S. aureus infection in past 3 months
  • Known infection in the past 2 weeks
  • Known HIV infection
  • Pregnancy or breast-feeding
  • Immunomodulatory drugs
  • Malignancy or treatment for malignancy within the past six months, other than basal cell, localized squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or early stage prostate cancer
  • investigational drugs, vaccines or products in the past 30 days
  • Hypersensitivity to components of StaphVAX

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00211913

United States, Virginia
Clinical Research Associates of Tidewater
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
Nabi Biopharmaceuticals
Study Director: Preston Holley, MD Nabi Biopharmaceuticals

Responsible Party: Matt Hohenboken, MD, PhD, Executive Director Clinical & Medical Affairs, Nai Biopharmaceuticals Identifier: NCT00211913     History of Changes
Other Study ID Numbers: Nabi-1366
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: January 4, 2008
Last Verified: December 2007

Additional relevant MeSH terms:
Cardiovascular Diseases
Staphylococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections